| 영문 | pelvic inflammatory disease | 한글 | 골반염질환 |
|---|---|---|---|
| 설명 | 골반주위의 장기에 발생하는 염증을 말함. 주로 여성에서 발생하며 원인은 임균(gonococcus)과 비임균에 의한 감염(non-gonorrheal infection)에 의한다. 증상은 초기에는 질분비물, 하복부동통, 여성의 생식기부위에 발생하는 압통, 월경통, 월경량의 증가 등이다. 일찍 치료해야 하며, 계속적으로 병이 지속시 여성의 불임의 원인이 된다. 후진국에서는 가장 많은 여성불임의 원인이기도 함. 치료는 항생제의 투여이다. |
||
| 영문 | inflammatory bowel disease | 한글 | 염증성창자병 |
|---|---|---|---|
| 설명 | 위장관을 침범하는 정확한 원인이 밝혀지지 않은 만성적인 염증성 질환을 말한다. 크게 ‘궤양성 대장염’(ulcerative colitis)과 ‘크론병’(Crohn's disease)의 두 종류로 구분된다. 백인, 유태인에 많고 흑인이나 동양인에는 드물지만 동양인에서 점차 증가추세에 있다. 호발연령은 15~35세 사이이다. 증상은 ‘궤양성 대장염’의 경우, 설사(혈변 및 점액변), 뒤무직, 복통, 복부압통, 체중감소 등이 주로 나타나며 ‘크론병’에서는 설사와 체중감소, 우하복부 종류, 항문주위 이상, 복부압통 등이 나타난다. 진단은 병력과 방사선학적 검사, 직장경 및 대장 내시경검사, 직장 및 대장의 조직검사로 하며 치료는 내과적인 치료가 원칙이나 내과적 치료에 듣지 않거나 합병증이 생길 경우에는 외과적 치료를 시행한다. ‘궤양성 대장염’의 경우에는 ‘대장암’을 예방하기 위해서 외과적 치료를 하기도 한다. ‘궤양성 대장염’과 ‘크론 병’외에 염증성 창자병에 속하는 ‘베체트 병’은 재발성 구강내 궤양, 피부 병변, 안구부 염증, 외음부 궤양, 관절염 증상, 위창자관 증상(복통, 장출혈), 부고환염 등의 증상을 나타내는데 진단과 치료는 ‘궤양성 대장염’, ‘크론 병’과 비슷하다. |
||
| 영문 | anti-inflammatory agent | 한글 | 항염증제, 소염제, 염증약 |
|---|---|---|---|
| 설명 | 국소에 작용하여 염증을 치료하고 방지하는 약. 염증을 가라앉히는 약을 말한다. 조직을 긴축-치밀하게 하여 장액과 점액의 분비를 줄이고, 표면에 있는 작은 혈관에 빈혈을 일으켜 충혈되는 것을 방지함으로써 염증적 병변을 제거하여 모든 증세를 없앤다. 대부분의 수렴제-완화제-진양제가 이에 속한다. 중요한 성분으로는 알루미늄-비스무트-아연-납화합물(병반-페르마톨-아연화-연당 등) 등이 있다. 작용에 따라 항염증진통제와 항염증효소제로 나뉜다. |
||
| CEA | Carcino-Embryonic Antigen [HP 1825-6] ; Oncofetal Antigens ; Glycopro... |
|---|---|
| AFP | Alpha(α) Feto-Protein [HP 1826, 1858, 1859, 2265] ; Oncofetal Antigens &nbs... |
| PAIN | pyoderma gangrenosum, aphthous stomatitis, inflammatory eye disease, erythema nodosum [disorders ass... |
| 131I | radioactive Iodine(used in Thyroid uptake, Liver & Kidney Scans & Treatment of malignant & nonmalig... |
| CHRONIC | chronic disease, rheumatoid arthritis, neoplasms, infections, cryoglobulinemia [conditions in which ... |
| ACSC | Ambulatory Care Sensitive Conditions |
|---|---|
| AIDP | Acute inflammatory demyelinating polyneuropathy |
| AIF-1 | Allograft Inflammatory Factor-1 |
| CIDP | Chronic Inflammatory Demyelinating Neuropathy |
| CIDP | Chronic Inflammatory Demyelinating Polyneuropathy |
| fibrous dysplasia of jaws | <radiology> Hereditary form of polyostotic fibrous dysplasia, involves mandible (12 Dec 1998) |
|---|---|
| precancerous conditions | Pathological processes that tend eventually to become malignant. (12 Dec 1998) |
| saline conditions | Soils or waters that are high in salt content, that is, more than 0.5 parts per thousand (=0.05% salinity). Usually sodium chloride (NaCl) is the predominant salt, but some areas have high concentrations of sulphates, carbonates, and bicarbonates, as well. Habitats are commonly subdivided on the basis of total salt content. (09 Oct 1997) |
| social conditions | The state of society as it exists or in flux. While it usually refers to society as a whole in a specified geographical or political region, it is applicable also to restricted strata of a society. (12 Dec 1998) |
| thermonuclear conditions | <radiobiology> Achievement of an adequately confined plasma, having temperature and density sufficiently high to yield significant release of energy from fusion reactions. (09 Oct 1997) |
| acute inflammatory polyneuropathy | <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin. The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months. Synonym: Guillain-Barre syndrome (12 Jul 2000) |
| anti-inflammatory | Counteracting or suppressing inflammation. (18 Nov 1997) |
| anti-inflammatory agent | Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |
| anti-inflammatory agent, steroidal | Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents. (12 Dec 1998) |
| anti-inflammatory agent, topical | Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application. (12 Dec 1998) |
| macrophage inflammatory protein | <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other. They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells. They most likely also play a significant role in respiratory tract defenses. (20 Sep 2002) |
| pelvic inflammatory disease | <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections. (27 Sep 1997) |
| chronic inflammatory demyelinating polyneuropathy | An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone. (05 Mar 2000) |
| chronic inflammatory polyneuropathy | <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response. The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable. Origin: Gr. Pathos = disease (27 Sep 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|